2026年11月4日星期三
M
مرآة العالم الشاملة
أخبار عالمية عاجلة
Vienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

المصدر Nature 生命科学قبل 1 يوم
ملخص المحتوى

يوفر هذا الموقع فقط فهرس العناوين والملخصات، والمحتوى الكامل وحقوق النشر مملوكة بالكامل للناشر الأصلي، يرجى النقر على رابط النص الأصلي للقراءة.

الانتقال إلى النص الأصلي
القناة التابعة
علوم
المنطقة التابعة
منظور عالمي
لغة النص الأصلي
English
رقم الإدخال
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · مرآة العالم الشاملة